Financial Performance - The company's operating revenue for 2022 was ¥974,293,135.49, representing a 9.78% increase compared to ¥887,484,877.11 in 2021[35]. - The net profit attributable to shareholders for 2022 was ¥101,163,536.29, an increase of 8.58% from ¥93,169,906.99 in the previous year[35]. - The basic earnings per share for 2022 was ¥1.18, up 8.26% from ¥1.09 in 2021[35]. - Total assets at the end of 2022 reached ¥1,930,786,964.46, a 45.15% increase from ¥1,330,174,616.17 at the end of 2021[35]. - The net assets attributable to shareholders at the end of 2022 were ¥929,650,723.07, reflecting a 17.47% increase from ¥791,384,719.19 in 2021[35]. - The cash flow from operating activities for 2022 was ¥125,362,160.61, an increase of 8.04% compared to ¥116,035,587.65 in 2021[35]. - The diluted earnings per share for 2022 was ¥1.17, which is a 7.34% increase from ¥1.09 in 2021[35]. - The weighted average return on equity for 2022 was 11.62%, down from 12.41% in 2021[35]. - The company's total revenue for Q4 2022 reached ¥280,845,440.49, showing a steady increase from ¥198,828,511.27 in Q1 2022[40]. - The net profit attributable to shareholders for Q3 2022 was ¥33,099,197.05, representing a significant increase compared to ¥20,081,539.34 in Q1 2022[40]. - The revenue from pharmaceutical manufacturing and sales accounted for 99.10% of total revenue, amounting to ¥965,504,941.23, with a year-on-year growth of 9.82%[105]. - The company's self-manufactured traditional Chinese medicine sales reached ¥555,499,826.12, contributing 57.02% to total revenue, with a growth of 9.32% year-on-year[107]. - The company reported a gross profit margin of 58.10% in the pharmaceutical manufacturing and sales sector, with a slight decrease of 0.29% compared to the previous year[107]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB in 2022, representing a year-over-year growth of 15%[161]. - The company provided a positive outlook for 2023, projecting a revenue growth of 10% to 1.32 billion RMB[163]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan for the year, representing a growth of 20% compared to the previous year[199]. Research and Development - The company is collaborating with Shaanxi Academy of Traditional Chinese Medicine to develop the innovative drug "Qingwen Hufei Granules" and has made progress in the clinical research of a coronavirus protease inhibitor[10]. - The company is actively involved in the research and development of new products, focusing on traditional Chinese medicine's unique advantages in disease prevention and treatment[54]. - The company has initiated 7 new research projects, focusing on innovative drug development and traditional medicine[96]. - The company aims to develop new products for osteoarthritis and coronavirus treatment, with several projects in various stages of development[118]. - The company plans to invest approximately 3% of its annual revenue into innovation and research and development to enhance its comprehensive strength in innovation[66]. - The company is committed to building a high-efficiency R&D team and enhancing collaboration with research institutions and universities to drive innovation[149]. - The company is focusing on the development of high-value new products and the transformation of research outcomes into marketable products[148]. - Investment in R&D has increased by 30%, focusing on innovative drug development and new technologies[199]. Market Expansion and Product Development - The company is launching a non-public offering of A-shares to expand its product pipeline, focusing on high-end external preparations and innovative Chinese medicine[10]. - The company aims to expand its market presence and enhance its service capabilities in the traditional Chinese medicine sector, supported by government initiatives[53]. - The company has expanded its product offerings to include health products such as oral health products, functional foods, and medical devices, enhancing market competitiveness[80]. - The company is focused on expanding its market presence in medical institutions and crowded public areas with its protective medical masks[65]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for potential mergers[161]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[199]. - The company aims to develop potential products like pediatric throat and tonsil granules and osteoporosis treasure tablets, targeting over 100 million in market potential[88]. Corporate Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring accurate and timely information disclosure[166]. - The board of directors consists of nine members, including three independent directors, meeting legal requirements for composition[170]. - The company has implemented a complete and independent financial accounting system, ensuring no shared bank accounts with the controlling shareholder[182]. - The company has a dedicated investor relations management system to ensure equal access to information for all shareholders[173]. - The company has established a clear governance structure with a board of directors, supervisory board, and shareholder meetings operating independently[183]. - The management team holds a significant number of shares, indicating alignment with shareholder interests[187]. - The company has demonstrated a commitment to maintaining operational independence and transparency in its governance practices[183]. Social Responsibility and Community Engagement - The company has established a charitable fund to support healthcare, education, and poverty alleviation initiatives[11]. - The company actively participates in rural revitalization and social responsibility initiatives, supporting vulnerable groups[155]. - The company is committed to green development, aiming to create eco-friendly factories and explore industrial tourism[154]. Industry Trends and Challenges - The Chinese traditional medicine industry is experiencing steady growth, supported by government policies and increasing public health awareness[46]. - The aging population in China is expected to drive demand for chronic disease medications, with over 1.9 billion elderly suffering from chronic diseases[48]. - The government emphasizes the importance of traditional Chinese medicine, which is expected to create new opportunities for the industry[47]. - The company acknowledges intensified market competition and intends to increase innovation and expand its brand influence[158]. - The company is aware of the risk of drug price reductions and is focusing on the development of its proprietary products to maintain price stability[159]. - The company faces risks from industry policy changes and plans to adjust its marketing strategies accordingly to enhance competitiveness[157].

Group 1: Research and Development Progress - The 3CL protease inhibitor project is in the preclinical research phase, developed in collaboration with Shaanxi University of Science and Technology [2] - The Qingfeng Hupai granules, based on traditional Chinese medicine, target mild COVID-19 symptoms and have been approved as a hospital preparation in Shaanxi Province [2][3] - The company signed a technical development contract with Shaanxi Traditional Chinese Medicine Research Institute to develop new herbal medicines for flu [3] Group 2: Product Development and Production - The company has expanded its production capabilities to include nine types of traditional Chinese medicine formulations, enhancing its competitive edge in hospital preparations [4] - The establishment of the Shaanxi Medical Institution Preparation Centralized Preparation Center has facilitated the signing of multiple processing agreements with medical institutions [4] - The company is developing transdermal drug delivery systems, including gel patches and hot melt adhesive patches, to enhance its product line [3] Group 3: Market Expansion and Sales Strategy - The company has established a comprehensive marketing network across 31 provinces, ensuring steady growth in performance [5] - The health product line includes six major categories, with significant sales growth driven by both online and offline channels [5] - The company is actively expanding into large supermarket markets and building specialized marketing teams [5] Group 4: Logistics and Distribution - The company’s pharmaceutical distribution network covers thousands of medical institutions in Shaanxi Province, ensuring comprehensive service delivery [6] - The company has obtained drug distribution rights through compliance with national quality management standards [6] - The logistics operations have seen steady growth, particularly during the pandemic, ensuring timely delivery of medical supplies [6] Group 5: Profitability and Future Planning - The company is focused on improving profitability through various strategies, including stabilizing raw material costs and optimizing product structure [6] - Plans include expanding the health business segment to create new profit growth points [6] - The company aims to enhance its research and development capabilities to foster innovative projects [6]

编号：2001-05-01 证券代码：002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □特定对象调研 □分析师会议 | | | | □媒体采访 | 业绩说明会 | | 投资者关系活动 | □新闻发布会 □路演活动 | | | 类别 | ...

编号：2021-08-02 证券代码：002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------|------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | | □媒体采访 | ☑ 业绩说明会 | | 投资者关系活 | □新闻发布会 □路演活动 | | | 动类别 | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称 | 通过" 同花顺路演平台 | "参与公司 2021 年半年度业绩说明会的广大投资者 | | 及人员姓名 | | | | 时间 | 2021 年 09 月 01 | 日（星期三） 15:00-16:30 | | 地点 | 同花顺 ...

编号：2021-08-01 证券代码：002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 编号：2001-07-01 | --- | --- | --- | --- | --- | |-----------------------------|----------------------------------------------------------------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...